Status:
NOT_YET_RECRUITING
Alzheimer's Tau Platform: Regimen A - AADvac1
Lead Sponsor:
Paul S. Aisen
Collaborating Sponsors:
Axon Neuroscience SE
University of California, San Francisco
Conditions:
Preclinical Alzheimer's Disease
Prodromal Alzheimer's Disease
Eligibility:
All Genders
50-80 years
Phase:
PHASE2
Brief Summary
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with an anti-amyloid monoclonal antibody...
Detailed Description
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with an anti-amyloid mAb, in adults aged...
Eligibility Criteria
Inclusion
- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).
Exclusion
- No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2028
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT07167966
Start Date
November 1 2025
End Date
August 31 2028
Last Update
September 26 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.